



- BUSINESS
- AUTOS
- TECH
- SPORTS
- ENTERTAINMENT
- POLITICS
- LIFE
- PERSONAL FINANCE

Like 37k

Follow

Search Quotes or News

# Urinary Catheter Supplies

[www.topcathetersupplies.com](http://www.topcathetersupplies.com)

Best Urinary Catheters Covered By Medicare. Free Home Shipping.

HOME / BREAKING NEWS /

## CytRx Is Heading to a Pivotal Trial

JOHN RIVERS | [MORE ARTICLES](#)  
FEBRUARY 04, 2014



Source: <http://www.flickr.com/photos/andresrueda/>

**CytRx Corp.** ([NASDAQ:CYTR](#)) is a U.S. research and biopharmaceutical company specializing in the field of oncology. The medical field of oncology is a branch of internal medicine and is concerned with early cancer recognition, cancer diagnosis, and treatment (including chemotherapy and radiotherapy), as well as post-

Advertisement

## HP Chromebook

[google.com/chromebook](http://google.com/chromebook)

Made with Google. For \$279. Everything you need in one laptop.

Advertisement

**Trade with TradeStation - Trade commission-free for 90 days.**  
[More.](#)

Advertisement

rehabilitation support. Cancer is a deadly disease and is characterized by uncontrolled abnormal cell growth.

Cancer can affect all vital organs of the human body (colon, lung, prostate, etc.), and it remains one of the most pressing public health concerns of our time. The American Cancer Association estimated that 1,660,290 new cancer cases would be diagnosed in the United States in 2013 alone and that 580,350 Americans would die as a result of cancer the same year. Cancer is responsible for one in four deaths in the United States, which highlights the importance of both early cancer recognition and the need for successful cancer therapies. Substantial research and development expenses are incurred by pharmaceutical companies in the U.S. and Europe to develop marketable solutions to the cancer epidemic.

## Background

CytRx's oncology pipeline accentuates the clinical development of doxorubicin, which aims to be a superior improvement over doxorubicin, a well-established chemotherapeutic agent. The development of doxorubicin seems to be a promising bet for CytRx as the company steadily progresses through the phases of the clinical research cycle.

CytRx's most recent 10-Q filing with the U.S. Securities and [Exchange Commission](#) summarized the development [portfolio](#) as follows:

“CytRx is conducting a global Phase 2b clinical trial with doxorubicin as a treatment for soft tissue sarcoma, has completed a Phase 1b/2 clinical trial primarily in the same indication, a Phase 1b study of doxorubicin in combination with doxorubicin in patients with advanced solid tumors, and a Phase 1b pharmacokinetics clinical trial in patients with metastatic solid tumors. CytRx plans to initiate under a Special Protocol Assessment, or “SPA,” granted by the U.S. Food and Drug Administration, or the “FDA,” a potential pivotal Phase 3 global trial of

## BROKER PARTNERS



Trade fre  
days and  
\$500.



Earn **300** commission-free  
online trades.  
Get details\*

Start trac  
Schwab

## STORIES YOU'LL LOVE



**Fight the Addiction:  
7 Ways to Stay  
Awake Without**


**Caffeine**



**Top 10 Healthiest  
Cities in the U.S.**



**Top 10 States With  
Exploding Home  
Prices**



**5 Must-Have Stocks  
in Your 2014  
Portfolio**



**8 Reasons Why the  
Lakers Are So  
Despondent Right**

aldoxorubicin as a therapy for patients with soft tissue sarcoma whose tumors have progressed following treatment with chemotherapy. The Company also is initiating Phase 2 clinical trials with aldoxorubicin in patients with late-stage glioblastoma (brain cancer) and AIDS-related Kaposi's sarcoma. CytRx plans to expand its pipeline of oncology candidates based on a linker platform technology that can be utilized with multiple chemotherapeutic agents and may allow for greater concentration of drug at tumor sites."

**Now****MORE MOST POPULAR »**

Advertisement

CytRx also holds exclusive worldwide rights to aldoxorubicin, which could lead to a large windfall in the future should aldoxorubicin make it through the clinical testing process and be approved by the U.S. Food and Drug Administration.

### Positive news flow

CytRx delivered a series of positive news lately, which drove the [share price](#) well above the \$7 mark. On December 11, the company released statistically significant results from its Phase 2b trial with aldoxorubicin in first-line soft tissue sarcomas. On January 21, the company reported that it received approval from the FDA to extend aldoxorubicin dosing cycles until disease progression in its upcoming pivotal global phase 3 trial for second-line soft tissue sarcomas.

As a reaction to the news, CytRx's share price jumped to \$7.76 up from a closing price of \$7.04 the previous Friday (an increase of 10 percent). On January 23, the company announced that it initiated an open-label Phase 2 clinical trial at Louisiana State University Health Sciences Center in New Orleans to determine preliminary efficacy and safety of aldoxorubicin for HIV-infected patients with Kaposi's sarcoma. In response to the news, shares of CytRx jumped 12 percent.

Advertisement


CytRx CEO and President Steven A. Kriegsman said: "Aldoxorubicin has demonstrated effectiveness against a range of tumors in both

human and animal studies, thus we are optimistic in regard to a potential treatment for Kaposi's sarcoma. The current standard-of-care for severe dermatological and systemic KS is liposomal doxorubicin (Doxil). However, many patients exhibit minimal to no clinical response to this agent, and that drug has significant toxicity and manufacturing issues."

Positive news flow with respect to aldoxorubicin and increased buyer interest after news dissemination show that CytRx's share price is highly news sensitive. Further positive news with respect to the initiation of CytRx's phase 3 clinical trial for second-line soft tissue sarcoma, which is expected in the first quarter of 2014, could be another substantial, short-term catalyst.

CytRx's [investor](#) presentation (especially valuable for investors who want to get a deeper understanding of pharmaceutical data relating to aldoxorubicin and doxorubicin) from December highlights a roadmap for CytRx's development portfolio, while every milestone achievement could be a meaningful catalyst for CytRx's share price.

Near-term catalysts with respect to CytRx's development portfolio are summarized in the chart below:



## Exercise of over-allotment options indicates strong investor demand for CytRx stock

On October 8, the company announced the public offering of 10 million shares at an offering price of \$2.25 for gross proceeds of \$22.5 million in order to [fund](#) the development of its aldoxorubicin agent. In addition, the company attached an over-allotment option to its offering in order to be able to cover stronger-than-anticipated investor demand. Given the progress the company has made with respect to the development of aldoxorubicin, CytRx ultimately sold an additional 1.5 million shares via the exercise of the over-allotment option for total gross proceeds of \$25.9 million.

Strong investor demand for secondary offerings and particularly the exercise of over-allotment options are usually bullish signs. I have also repeatedly written that above-average returns can often be found in [investments](#) that fly below the radar. Smaller capitalization companies like CytRx (the company currently fetches a [market capitalization](#) of \$305 million) are typically under-covered by research firms, which makes it likely that security prices are not as efficient as those for larger capitalization companies.

### Conclusion

CytRx pursues the ambitious goal of replacing the standard chemotherapeutic agent doxorubicin with aldoxorubicin, an agent that appears to have better efficacy and safety. If CytRx's past share performance is any indicator of its future performance, investors can expect future news releases with respect to milestone achievements in its product portfolio to be highly security sensitive. Strong investor demand for CytRx's secondary [stock offering](#) also indicates that interest in aldoxorubicin and its possible applications in cancer treatments is high.

In anticipation of strong news flow, CytRx's shares have increased by more than 200 percent since December 10. If CytRx delivers positive results for its three clinical trials and manages to get FDA approval for its blockbuster product aldoxorubicin, the share price could run

substantially higher. The fact that CytRx holds the exclusive worldwide rights to adoxorubicin only adds to the appeal of this under-followed biopharmaceutical play.



**Don't Miss:** [You Snooze, You Lose: 7 Tips for Working Out in the AM.](#)

+ reddit this!

## See Also

1.
2.
3.

**4 Hormones All Skinny People Have In Balance**  
Real Dose

**1 Super Food That Burns Stored Fat Like A Furnace**  
Living Well

**Forget Tattooing Your Brows And Try This...**  
Dermstore

**14 Benefits Most Seniors Didn't Know They Had**  
Newsmax

**The New Diet Pill That Has Doctors Raving**

All Consumer Health Tips

**30 Fairly Shocking Pictures of Celebrities Without Makeup**

CelebrityToob

**Actress Has Wardrobe Malfunction So Bad You Won't Believe It (PHOTO)**

Stirring Daily

**Check Out These Celebrity Bikini Bodies**

MyDailyMoment

Sponsored Content by Taboola

## You Will Turn Off Your TV

Television is on its way out. And you're going to be thrilled. Because that means... as soon as 2014, you could ditch your cable company... along with all the headaches.

But that also means the \$2.2 trillion entertainment industry is up for grabs. And The Motley Fool knows exactly which three companies are poised to hijack your cable provider's profits. Our newest FREE report details everything you need to know to line your pockets as cable crumbles..

**Click Here, It's Free!**[The Motley Fool Terms And Conditions](#)[Wall St. Cheat Sheet Privacy Policy](#)[Wall St. Cheat Sheet Legal Disclaimer](#)More Articles About: [biopharmaceuticals](#) [CytRx Corp.](#) [drug pipeline](#)[Investing](#) [oncology](#) [pharmaceuticals](#) [pharmacy](#) [positive news](#)[positive news flow](#) [research and development](#) [share prices](#) [shares](#)[Steven A. Kriegsman](#) [Stocks](#) [Wall Street](#)

*To contact the reporter on this story:*

*staff.writers@wallstcheatsheet.com*

*To contact the editor responsible for this story:*

*editors@wallstcheatsheet.com*



Add a comment...

Co

Facebook social plugin

# Master in Aging Services

agingmgmt.usc.edu

Earn Your Masters in Aging Services in Just 18 Months, Online at USC.

**Wall St. Cheat Sheet has been featured in these fine media outlets:**



- |                                  |                                  |                          |   |
|----------------------------------|----------------------------------|--------------------------|---|
| <a href="#">Login</a>            | <a href="#">Jobs</a>             | <a href="#">Google+</a>  | <a href="#">STOCK INVESTOR CHEAT SHEET</a>              |
| <a href="#">About Us</a>         | <a href="#">Affiliates</a>       | <a href="#">Facebook</a> | <a href="#">GOLD &amp; SILVER INVESTMENT NEWSLETTER</a> |
| <a href="#">Customer Support</a> | <a href="#">Archive</a>          | <a href="#">Twitter</a>  | <a href="#">COMMODITIES INVESTMENT NEWSLETTER</a>       |
| <a href="#">Contact Us</a>       | <a href="#">Legal Disclaimer</a> | <a href="#">Linkedin</a> | <a href="#">WEEKLY STOCK CHEAT SHEETS</a>               |
|                                  | <a href="#">Policy</a>           | <a href="#">Email</a>    |   |

© & ® 2014 Wall St. Cheat Sheet, All Rights Reserved

